LegoChem Biosciences announced yesterday the conclusion of an exclusive licensing agreement with Janssen Biotech, under which the South Korean laboratory will grant the J&J subsidiary the rights to one of its conjugated antibodies (CDAs).

Under the terms of the agreement, Innate has received an upfront payment of $100 million, and will be entitled to receive up to a further $200 million if the option for LCB84 is exercised.

Taking into account development, regulatory and commercial milestone payments, LegoChem estimates that it could receive total royalties of $1.7 billion on potential sales of the product.

LCB84, currently in Phase 1/2 clinical trials in the U.S., features a differentiated mechanism of action, as it targets the Trop2 antigen, highly expressed in cancer cells.

Copyright (c) 2023 CercleFinance.com. All rights reserved.